Carl Zeiss Meditec’s re-rating journey should continue further
21/02/24 -"Despite our near-term estimates being slightly moderated due to the destocking of consumables and anticipated impact from volume-based procurement headwinds, our target price resets higher by c.4%, ..."
Pages
60
Language
English
Published on
21/02/24
You may also be interested by these reports :
24/02/26
FMC delivered a strong Q4 profit beat, with record profitability driven by accelerated FME25+ savings and operational discipline. FY 25 results also ...
23/02/26
Considering the lower medium-to-long-term expectations, the premium for peer-based metrics has been reduced to 25% (vs. 50% previously). However, ...
20/02/26
Since we began coverage on Elekta (BUY; Sweden) in January 2020, medical equipment and software provider for cancer treatment using radiation ...
18/02/26
Emeis delivered a robust operational recovery in 2025, characterised by EBITDAR growth that exceeded management guidance and a further strengthened ...